한국어
Quantus

ORIENT BIO

002630 · KOSPI
₩913+0.00%
2026-09-04 close

ORIENT BIO last closed at ₩913 (+0.00%) on 2026-09-04. Listed on KOSPI; price, financials and dividends update daily after market close.

Loading chart…
Close
No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p

Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

B+
Overall: 건강관리 98/291 · top 33%
Factor composite · relative position in sector

PER — · PBR 0.75 — own-history percentile 5/100 · 96/100

Open self-history band
PER5/100
PBR96/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Financial safety

Reference indicatorAs of 2025
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 9.04
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
9.04
Beneish M-Score
-3.31

No statistical flag

Sloan accrual
-16.45%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Why has this company moved this way?

Auditable observations with the original numeric evidence.

차입 증가 → 이자부담 → 수익성 악화

Critical

부채가 +8.8% 늘며 이자보상배율이 -11.4x에서 -14.0x로 하락했다. ROE도 -0.8%에서 -4.3%로 낮아져 차입 부담이 수익성을 누르고 있다.

Evidence

부채 YoY +8.8%이자보상배율 -11.4x→-14.0xROE -0.8%→-4.3%

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

4/9Moderate

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score4/9

Profitability

  • Positive ROANot passed
  • Positive OCFPass
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesPass

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Margin trendWarning

영업이익률 악화 (-2.3% → -10.5%, -8.2%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업외손익 급변 (영업이익 대비 768% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

KRAs of 2026-09-05

건강관리

This stock is in 건강관리: revenue rank 191 of 287, share 0%.

191 / 2870%revenue share

Who dominates this industry?

  1. 1삼성바이오로직스7.3%
  2. 2셀트리온5.7%
  3. 3녹십자홀딩스3.5%
  4. 4유한양행3.3%
  5. 5대웅3.1%
  6. 6오리엔트바이오0%

Concentration

DistributedCR3 16.6%
HHI 202287 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
31.61
Direction
확대
Level
넓음
Years
7

Value lens

P90/P10
13.9
Median P/B
1.47
Level
넓음
n
263

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-10.5%
Interest coverage
-14x
Return on equity (ROE)
-18.4%

Operating margin −5pp

Operating loss
Interest coverageBase -14x adverse case -20.6x
Return on equity (ROE)Base -18.4% adverse case -6.6%

Revenue −15%

Interest coverage risk
Interest coverageBase -14x adverse case -11.9x
Return on equity (ROE)Base -18.4% adverse case -3.9%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -14x adverse case -6.4x
Return on equity (ROE)Base -18.4% adverse case -4.9%

Interest coverage limit

Already below the limit by 11.2pp

Interest coverage limit at an operating margin of 0.7%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-06-19

Suppliers disclosed by the company in its 2026-06-19 annual report.

Purchase amount

KRW 100m
  1. 오리엔트
    KRW 130.3B
  2. ORIENTAL
    KRW 39B
  3. YEAST
    KRW 39B
  4. NORTHEASTERN
    KRW 35.7B
  5. PRO
    KRW 35.7B

Suppliers without disclosed amount

상기PMINUTRITIONINTERNATION

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

  • 오리엔트39.65%2026-07-23 · 증감 +2.55%p

Other stocks held by the same investors

A filing-based shared-holder record, not investment advice.

Connections

AI-extracted related companies · for reference

Suppliers
Thermo Fisher ScientificMerck KGaASartoriusDanaher
Customers
AbbVie
🔗 See in the full market map →

Recent filings

ORIENT BIO's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

About ORIENT BIO
What technical signals does ORIENT BIO (002630) have?
ORIENT BIO current technical signals: no active technical signal.
Is ORIENT BIO a cup-and-handle pattern?
No. ORIENT BIO has no valid cup-and-handle signal right now.
What are ORIENT BIO's financials and valuation?
ORIENT BIO's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy